Omada Health shares jumped after the company made its public-market debut, propelled by Americans’ renewed focus on how ...

Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs such ...

GLP-1 drugs alter taste perception… and commonly disrupt the perception of sweetness, bitterness, fatty foods and even ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

The mother-of-two was surprised to find out that she was pregnant with another child after struggling to conceive in the past ...

We've all heard eating less sugar helps melt off spare pounds. Yet it often feels too darn hard. So we were excited when we ...

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The ...

On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

The European Medicines Agency has identified a rare eye condition risk linked to Novo Nordisk’s semaglutide drugs.

The petition, filed by Massachusetts, New York, California, and New Jersey, aims to compel the FDA to recognize that mifepristone is safe and effective. More reproductive health news includes GLP-1 ...